Cargando…
Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212477/ http://dx.doi.org/10.1016/S0016-5085(22)60679-6 |
| _version_ | 1784730603523932160 |
|---|---|
| author | Joergensen, Kristin K. Syversen, Silje W Jyssum, ingrid Tveter, Anne Therese Tran, Trung T. Sexton, Joe Provan, Sella A. Mjaaland, Siri Warren, David J. Kvien, Tore K. Gr⊘deland, Gunnveig Nissen-Meyer, Lise Sofie H. Ricanek, Petr Chopra, Adity Anderson, Ane M. Kro, Grete B. Munthe, Ludvig A. Haavardsholm, Espen A. Vaage, John T.T. Lund-Johansen, Fridtjof Jahnsen, Jorgen Goll, Guro L. |
| author_facet | Joergensen, Kristin K. Syversen, Silje W Jyssum, ingrid Tveter, Anne Therese Tran, Trung T. Sexton, Joe Provan, Sella A. Mjaaland, Siri Warren, David J. Kvien, Tore K. Gr⊘deland, Gunnveig Nissen-Meyer, Lise Sofie H. Ricanek, Petr Chopra, Adity Anderson, Ane M. Kro, Grete B. Munthe, Ludvig A. Haavardsholm, Espen A. Vaage, John T.T. Lund-Johansen, Fridtjof Jahnsen, Jorgen Goll, Guro L. |
| author_sort | Joergensen, Kristin K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212477 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92124772022-06-22 Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY Joergensen, Kristin K. Syversen, Silje W Jyssum, ingrid Tveter, Anne Therese Tran, Trung T. Sexton, Joe Provan, Sella A. Mjaaland, Siri Warren, David J. Kvien, Tore K. Gr⊘deland, Gunnveig Nissen-Meyer, Lise Sofie H. Ricanek, Petr Chopra, Adity Anderson, Ane M. Kro, Grete B. Munthe, Ludvig A. Haavardsholm, Espen A. Vaage, John T.T. Lund-Johansen, Fridtjof Jahnsen, Jorgen Goll, Guro L. Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212477/ http://dx.doi.org/10.1016/S0016-5085(22)60679-6 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Joergensen, Kristin K. Syversen, Silje W Jyssum, ingrid Tveter, Anne Therese Tran, Trung T. Sexton, Joe Provan, Sella A. Mjaaland, Siri Warren, David J. Kvien, Tore K. Gr⊘deland, Gunnveig Nissen-Meyer, Lise Sofie H. Ricanek, Petr Chopra, Adity Anderson, Ane M. Kro, Grete B. Munthe, Ludvig A. Haavardsholm, Espen A. Vaage, John T.T. Lund-Johansen, Fridtjof Jahnsen, Jorgen Goll, Guro L. Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY |
| title | Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY |
| title_full | Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY |
| title_fullStr | Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY |
| title_full_unstemmed | Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY |
| title_short | Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY |
| title_sort | sa1052: immunogenicity and safety of standard and third dose sars-cov-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212477/ http://dx.doi.org/10.1016/S0016-5085(22)60679-6 |
| work_keys_str_mv | AT joergensenkristink sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT syversensiljew sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT jyssumingrid sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT tveterannetherese sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT trantrungt sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT sextonjoe sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT provansellaa sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT mjaalandsiri sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT warrendavidj sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT kvientorek sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT grdelandgunnveig sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT nissenmeyerlisesofieh sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT ricanekpetr sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT chopraadity sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT andersonanem sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT krogreteb sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT muntheludviga sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT haavardsholmespena sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT vaagejohntt sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT lundjohansenfridtjof sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT jahnsenjorgen sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy AT gollgurol sa1052immunogenicityandsafetyofstandardandthirddosesarscov2vaccinationinpatientswithimmunemediatedinflammatorydiseasesaprospectivecohortstudy |